Scarica l'app Stockscreener
0.8301
2.23%
-0.0189
Dopo l'orario di chiusura:
.83
-0.000100
-0.01%
Inflarx N V Borsa (IFRX) Ultime notizie
InflaRx (NASDAQ:IFRX) Short Interest Update - Defense World
InflaRx (NASDAQ:IFRX) Price Target Cut to $3.00 by Analysts at Oppenheimer - Defense World
InflaRx stock rating cut, price target slashed to $2 by Raymond James - Investing.com Nigeria
InflaRx (IFRX) Maintains Outperform Rating, Price Target Adjusted | IFRX Stock News - GuruFocus
IFRX Price Target Cut as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
Oppenheimer Adjusts Price Target on InflaRx N.V to $3 From $6, Maintains Outperform Rating - marketscreener.com
Raymond James Downgrades InflaRx to Outperform From Strong Buy, Price Target is $13 - marketscreener.com
Guggenheim maintains $10 target on Inflarx despite study halt - Investing.com Australia
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Sto - GuruFocus
InflaRx (IFRX) Faces Downgrade as Phase 3 Trial Halts | IFRX Stock News - GuruFocus
InflaRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
Top Midday Decliners - marketscreener.com
Crude Oil Gains 2%; Macy's Lowers Earnings Forecast - Benzinga
Guggenheim maintains $10 target on Inflarx despite study halt By Investing.com - Investing.com Nigeria
InflaRx Ends Lead Asset Development After Failed Study For Rare And Painful Skin Disease - Benzinga
PG rating: Inflarx review declares phase III bomb - BioWorld MedTech
InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial - insights.citeline.com
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
InflaRx (IFRX) Halts Key Drug Trials, Refocuses Strategy - GuruFocus
InflaRx Halts Vilobelimab Phase 3 Trial for Pyoderma Gangrenosum - TipRanks
InflaRx to Discontinue Vilobelimab Development for Skin Disease Treatment; Shares Down Pre-Bell - marketscreener.com
InflaRx stock plunges on plans to drop lead asset (IFRX:NASDAQ) - Seeking Alpha
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus - GuruFocus
InflaRx to discontinue vilobelimab indication following IDMC recommendation - TipRanks
InflaRx (IFRX) Halts Phase 3 Trial for Vilobelimab, Shifts Focus | IFRX Stock News - GuruFocus
InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum - GlobeNewswire
Clinical Trial Setback: InflaRx Discontinues Key Drug Program After Phase 3 Futility Results - Stock Titan
InflaRx (NASDAQ:IFRX) Shares Acquired by Northern Trust Corp - Defense World
InflaRx to Participate in Upcoming Investor Conferences - The Manila Times
InflaRx Sets Ambitious Investor Conference Tour: Jefferies, Oppenheimer, and Leerink Partners Ahead - Stock Titan
Cubist Systematic Strategies LLC Makes New Investment in InflaRx (NASDAQ:IFRX) - Defense World
Schonfeld Strategic Advisors LLC Sells 7,756 Shares of InflaRx (NASDAQ:IFRX) - Defense World
Certain Pre-Funded Warrants of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Options of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Certain Ordinary Shares of InflaRx N.V. are subject to a Lock-Up Agreement Ending on 15-MAY-2025. - marketscreener.com
Raymond James maintains Strong Buy on Inflarx stock, $13 target By Investing.com - Investing.com Nigeria
Raymond James maintains Strong Buy on Inflarx stock, $13 target - Investing.com
FY2025 EPS Estimates for InflaRx Raised by Cantor Fitzgerald - Defense World
Q2 Earnings Forecast for InflaRx Issued By Leerink Partnrs - Defense World
InflaRx First Quarter 2025 Earnings: €0.13 loss per share (vs €0.16 loss in 1Q 2024) - Yahoo Finance
Oppenheimer Initiates Coverage of InflaRx N.V. (IFRX) with Outperform Recommendation - Nasdaq
This Centessa Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday - Benzinga
InflaRx N.V. Reports Q1 2025 Financial Results - TipRanks
InflaRx reports Q1 EPS (EUR 0.13) vs (EUR 0.17) last year - TipRanks
InflaRx Reports Q1 2025 Financial Results with Reduced Losses - TipRanks
InflaRx (IFRX) Awaits Key Milestones in Drug Development | IFRX Stock News - GuruFocus
InflaRx N.V. Announces Progress in Toxicology Studies for INF904 and Upcoming Phase 3 Interim Analysis of Vilobelimab - Nasdaq
InflaRx Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
InflaRx NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Grows Stake in InflaRx (NASDAQ:IFRX) - Defense World
InflaRx To Reveal Next Month Its Late-Stage Interim Results Of Lead Drug In Painful Ulcer - RTTNews
InflaRx (NASDAQ:IFRX) Earns Overweight Rating from Analysts at Cantor Fitzgerald - Defense World
Cantor Fitzgerald Predicts InflaRx FY2025 Earnings - Defense World
InflaRx (IFRX) Projected to Post Quarterly Earnings on Wednesday - Defense World
What is InflaRx N.V (IFRX) Stock Return on Shareholders’ Capital? - Sete News
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):